GLP-2 Drug Shows Steady Growth during Forecast Period due to Popularity
According to the research report, the global short bowel syndrome (SBS) market is expected to be worth US$2.6 bn by the end of 2024 as compared to be US$312.7 mn in 2016. Between the years of 2016 and 2024, the global market is expected to rise at a CAGR of 30.4%.
On the basis of drug class, the global market is segmented into GLP-2, glutamine, and growth hormone. Of these, the GLP-2 drug is estimated to rise at a CAGR of 36.0% between 2016 and 2024. Sold under the brand name of Gattex in the U.S. and Revestive in Europe, the GLP-2 drug is expected to make a significant contribution to the rising revenue of the global market due to its exclusivity. On the basis of geography, North America is anticipated to lead the global market as it progresses at a CAGR of 32.7% between 2016 and 2024.
Download PDF Brochure of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13346
High Cost of Parenteral Nutrition Steers Attention toward SBS Drugs
The high cost of parenteral nutrition, which is administered to the patient to allow the intestine to adapt to the changes and to maintain hemostasis, is anticipated drive the global market. The unaffordability of parenteral nutrition has significantly spiked the demand for short bowel syndrome drugs as they also help in reducing patient's dependence on parenteral nutrition, as has been observed in the clinical trials. The overall market is also being driven by the growing number of favorable reimbursements offered by the governments across North America. Additionally, assistance offered to patients on Gattex by Shire PLc is also estimated to work in favor of the market's growth.
Due to the rarity of this disease, the rate of diagnosis has been relatively low for short bowel syndrome. Furthermore, the approved drugs for SBS are not easily available across the globe, which has resulted in a significant pool of unmet clinical needs. In light of these reasons, the global market is expected to find several lucrative opportunities in the coming years. The growing investments and focus of several associations and foundations in raising awareness about short bowel syndrome has played a crucial role in defining the positive trajectory of the global market. Currently, The National Organization for Rare Disorders and its member organizations, such as the Association of Gastrointestinal Motility Disorders, Inc., the Oley Foundation, the SBS Cure Project, and the Short Bowel Syndrome Foundation, Inc. are raising awareness about the diseases amongst people. Drug manufacturers are also initiating awareness programs to offer assistance to patients and earn high revenues.
Adverse Side Effects of SBS Drugs to Restrain Market Growth
The key drawback for the global short bowel syndrome market is the side-effect of taking short bowel syndrome drugs. The drugs approved for treating SBS are associated with a wide range of side effects that can lead to several health complications. For instance, the commonly seen effects of Revestive or Gattex are nausea, abdominal pain, cold, flu, and headache among others. These medicines can also lead to complications pertaining to blockage of the bowel, polyps in the colon, abnormal cell growth resulting in cancer, and inflammation or blockage of gallbladder or pancreas. The market is also likely to be affected by the high mortality rate associated with SBS and non-availability of approved drugs, especially in the developing economies.
Request for Report Customization:
This review is based on Transparency Market Research report, titled "Short Bowel Syndrome Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024."
The Short Bowel Syndrome Market has been segmented as follows:
- Short Bowel Syndrome Market, by Drug Class, Revenue (US$ Mn) 2014-2024
- Growth Hormone
- Short Bowel Syndrome Market Revenue, by Geography (US$ Mn), 2014-2024
- North America
- Rest of Europe
- Rest of the World
Browse Related Research Report:
Cervical Dysplasia Market (Diagnostics - Diagnostic Tests (Pap Smear Test, HPV Test, Biopsy), Diagnostic Devices (Colposcopy); End User - Hospitals, Diagnostic Centers, Private Gynecologists' Offices, Research and Academic Institutes, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
Bovine Respiratory Disease Treatment Market (Treatment Type - Vaccines, Antibiotics, NSAIDs, and Immunomodulators; Disease Type - Upper Respiratory Tract Infections, Pneumonia (Lower Respiratory Tract Infection), and Diphtheria; Distribution Channel - Veterinary Hospitals, Veterinary Clinics, Private Veterinary Pharmacies, and Veterinary Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Point-of-care Diagnostics Market (Product - Lateral Flow Assay Test, Flow-through Test, Solid Phase Assay Test, and Agglutination Assay Test; Application - Infectious Disease Test, Cholesterol Monitoring, Substance Abuse Test, Fertility and Pregnancy Test, and Blood Glucose Test; End Users - Hospitals, Clinics, Homecare Settings, and Diagnostic Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
SOURCE Transparency Market Research